There is a lot of excitement in the air about the use and further development of immunotherapies in oncology. For many, this is a huge step change in the positive direction for how physicians will treat cancer patients in the future. There is much hope, despite some initial concerns about reduced efficacy in some patient…
What is Indication-specific Pricing? Manufacturers have traditionally charged the same price for a drug regardless of the indication in question. With the new “indication-specific pricing” model, it is suggested that prices for a drug vary depending on the perceived “value/ benefit” of the drug in different indications. Source: 2015 ICER Membership Policy Summit Report…
Today, checkpoint inhibitor immuno-oncology (I-O) treatments are all the rage! Unlike traditional chemotherapies, I-O drugs enable a patient’s own immune system to identify and attack foreign cancer cells while leaving normal cells to continue to function unharmed. This is a huge opportunity to beef up cancer killing while maintaining the integrity of a patient’s quality…
Making the decision to launch a new prescription pharmaceutical product in Canada is often based on the likelihood of being able to secure the globally approved price through the PMPRB (Pharmaceutical Manufacturer’s Pricing Review Board) as well as prospective reimbursement through private and/ or public payers. If there appears to be a good estimated return on…
Before a new product launches, many manufacturers need to decide if they are going to initiate a Special Access Program (SAP) (also referred to as an Early Access Program [EAP] in the US or a Compassionate Use Program [CUP] or Named Patient Program [NPP] in the EU) for their brand while they are going through regulatory approval. The…
The Canadian pharmaceutical market access environment can be quite complex at first blush. There are many agencies, organizations, and bodies to conform with along with a myriad of legislative bills and protocols to understand. This will be the first of many blogs that Impetus will create to help demystify this complex ecosystem in Canada. Our…
Impetus Digital’s market access virtual advisory board consists of 7 of the top ex-payers in Canada who are subject matter experts in pricing and market access submission processes. Our goal is to provide market access, reimbursement, pricing, and health economics managers within Canadian pharma companies quick and economical access to key insights that will help…